News
Immodulon announces allowability of claims for key European patent application related to lead drug candidate, IMM-101, in combination with immune checkpoint inhibitors
Immodulon announces allowability of claims for key European patent application related to lead drug candidate, IMM-101, in combination with immune checkpoint inhibitors Claims cover IMM-101 in combination with any anti-PD-L1, anti-PD1 or anti-CLTA-4 monoclonal...
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center Erasmus MC initiates recruitment for new investigator-sponsored phase I/II study to investigate the safety and efficacy of...
Immodulon to present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event on clinical biomarkerstrategies with complex immunomodulators
Presentation on circulatory immunological biomarkers in cancer patients and novel technologies during clinical trials Uxbridge, UK – 15 March 2021 – Immodulon, the immuno-oncology company, announces that its Chief Scientific Officer, Dr. Thomas Kleen, will present at...
Immodulon announces Notices of Allowance and Intention to Grant for four patent applications related to IMM-101 in combination with immune checkpoint inhibitors in US, Japan and Europe
Claims cover methods of treating cancer with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies Uxbridge, UK, 8 March 2021 – Immodulon, the immuno-oncology company, today announced that it has received Notices of Allowance from the U.S. Patent...
Immodulon and Champalimaud Foundation announce collaboration to investigate IMM-101 in difficult to treat cancers
Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma Uxbridge, UK and Lisbon, Portugal – 3 August 2020 –...
Expansion of collaboration with Erasmus Medical Centre in metastatic pancreatic cancer
Additional investigator-initiated phase I/II study planned to investigate the safety and efficacy of IMM101 in limited metastatic pancreatic cancer; study could start by the end of 2020 Uxbridge, UK – 27 July 2020 – Immodulon, the immuno-oncology company, is pleased...
Immodulon announces that IMM-101 will be evaluated in world-first, prophylactic immuneboosting strategy for COVID-19 in cancer patients
Phase 3 study approved by Health Canada seeks to boost cancer patients’ immune systems with IMM-101 to protect against severe COVID-19 and other viral lung infections Uxbridge, UK – 9 July 2020 – Immodulon, the immuno-oncology company, is pleased to note that a...
Immodulon announces FDA clearance to proceed with the investigation of IMM-101 in a phase I/II study in advanced sarcoma
The phase I/II trial will recruit up to 42 participants with inoperable leiomyosarcoma or dedifferentiated liposarcoma Uxbridge, UK – 28 May 2020 – Immodulon, the immuno-oncology company, today announces that the Company has received confirmation from the US Food and...